Meta Information
ID:empagliflozin
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/class/diuretics
Target name:
Diuretics (Water Pills)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Empagliflozin acts as an osmotic diuretic; combining it with other diuretics greatly increases the risk of volume depletion, dehydration, low blood pressure, and kidney injury.
Actionable advice:
Use with extreme caution and monitor hydration, blood pressure, and kidney function closely.
Target id:
/intervention/insulin
Target name:
Insulin
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Empagliflozin lowers blood glucose independently of insulin. When combined with insulin, the risk of severe hypoglycemia (low blood sugar) is significantly increased.
Actionable advice:
The dose of insulin will likely need to be reduced when starting empagliflozin; monitor blood glucose frequently.
Target id:
/class/antidiabetic-medications
Target name:
Insulin Secretagogues (e.g., Sulfonylureas, Glinides)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
When combined with drugs that stimulate insulin secretion (like sulfonylureas), empagliflozin significantly increases the risk of severe hypoglycemia (low blood sugar).
Actionable advice:
The dose of the insulin secretagogue may need to be reduced when starting empagliflozin.
Target id:
/dietary/ketogenic-diet
Target name:
Ketogenic Diet
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Both empagliflozin and a ketogenic diet promote the production of ketones. Their combined use dramatically increases the risk of developing euglycemic ketoacidosis, a serious medical emergency where the blood becomes too acidic even with normal blood sugar.
Actionable advice:
Avoid following a strict ketogenic diet while taking empagliflozin.
Target id:
/procedure/major-surgery
Target name:
Major Surgery or Procedure
Severity:
major
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
72
Hours after target:
null
Description:
The metabolic stress of surgery, combined with required fasting, increases the risk of euglycemic ketoacidosis. Empagliflozin must be temporarily discontinued to mitigate this risk.
Actionable advice:
Stop taking empagliflozin at least 3 days before any scheduled major surgery or procedure.
Target id:
/condition/dehydration
Target name:
Dehydration or Acute Illness
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
During acute illness with vomiting, diarrhea, or fever, the risk of dehydration and ketoacidosis is high. The diuretic effect of empagliflozin can dangerously worsen this situation.
Actionable advice:
Temporarily stop taking empagliflozin if you are sick and unable to maintain normal fluid intake.
Target id:
/condition/renal-impairment
Target name:
Severe Renal Impairment (eGFR < 30)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Empagliflozin is not recommended for patients with severely impaired kidney function (eGFR < 30 mL/min/1.73 m2) as its glucose-lowering effectiveness is reduced and the risk of adverse effects increases.
Actionable advice:
Do not use if you have severe kidney disease; regular monitoring of kidney function is required for all users.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Empagliflozin is not recommended during the second and third trimesters of pregnancy due to potential risks of adverse kidney development and function in the fetus.
Actionable advice:
Avoid completely during pregnancy.
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is not known if empagliflozin passes into breast milk, but due to the potential for serious adverse reactions in a nursing infant, it is not recommended.
Actionable advice:
Avoid completely while breastfeeding.
Target id:
/condition/type-1-diabetes
Target name:
Type 1 Diabetes
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Use in patients with Type 1 Diabetes is associated with a much higher risk of developing diabetic ketoacidosis (DKA), even with normal or only mildly elevated blood sugar levels.
Actionable advice:
Avoid use in Type 1 Diabetes unless under the strict supervision of an endocrinologist.
Target id:
/dietary/water
Target name:
Adequate Fluid Intake
Severity:
major
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
Empagliflozin causes fluid and glucose loss through urination. Maintaining adequate hydration is essential to prevent dehydration, low blood pressure, and kidney problems.
Actionable advice:
Drink plenty of fluids throughout the day to stay well-hydrated.
Target id:
/class/nephrotoxic-agents
Target name:
Nephrotoxic Agents (NSAIDs, ACEi, ARBs)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Combining empagliflozin with drugs like NSAIDs, ACE inhibitors, or ARBs can impair kidney function, especially during illness or dehydration, increasing the risk of acute kidney injury.
Actionable advice:
Use this combination with caution, ensure adequate hydration, and monitor kidney function regularly.
Target id:
/dietary/alcohol-acute
Target name:
Alcohol
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Excessive alcohol consumption can increase the risk of both hypoglycemia and ketoacidosis, and can worsen dehydration caused by empagliflozin.
Actionable advice:
Limit alcohol intake and avoid binge drinking while taking this medication.
Target id:
/class/broad-spectrum-inducers
Target name:
UGT Enzyme Inducers (e.g., Rifampin, Phenytoin)
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Certain medications (like rifampin) can accelerate the breakdown of empagliflozin via UGT enzymes, reducing its concentration in the blood and potentially making it less effective.
Actionable advice:
If co-administration is necessary, monitor blood glucose closely as a higher dose of empagliflozin may be needed.
Target id:
/intervention/lithium
Target name:
Lithium
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Empagliflozin's diuretic effect can increase the kidney's excretion of lithium, potentially lowering its blood levels and reducing its therapeutic effect for mood stabilization.
Actionable advice:
Monitor lithium levels closely if starting or stopping empagliflozin; dose adjustments may be required.
Target id:
/condition/geriatric
Target name:
Geriatric (Older Adults)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Older adults may be more susceptible to the diuretic effects of empagliflozin, leading to a higher risk of dehydration, low blood pressure, dizziness, and falls.
Actionable advice:
Use with caution in older adults, ensuring adequate hydration and monitoring for dizziness.
Target id:
/circadian/wake
Target name:
Waking Up / Morning Routine
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
null
Hours after target:
1
Description:
Taking empagliflozin in the morning allows its diuretic effect to occur primarily during waking hours, reducing the likelihood of sleep disruption from nighttime urination (nocturia).
Actionable advice:
Take your dose once daily in the morning, with or without food.
Target id:
/class/glucose-lowering-supplements
Target name:
Glucose-Lowering Supplements (e.g., Berberine)
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Supplements that lower blood sugar can have an additive effect with empagliflozin, slightly increasing the risk of hypoglycemia.
Actionable advice:
Monitor blood glucose levels when adding new glucose-lowering supplements to your regimen.
Target id:
/biomarker/urine-glucose-test
Target name:
Urine Glucose Test
Severity:
major
Interaction type:
assay_interference
Nature:
absolute
Temporal spacing:
null
Description:
Empagliflozin works by causing glucose to be excreted in the urine. Therefore, urine glucose tests will always be positive and cannot be used to monitor blood sugar control.
Actionable advice:
Do not use urine glucose tests to monitor blood sugar; rely on blood tests like HbA1c or a blood glucose meter.
Target id:
/biomarker/1-5-ag-assay
Target name:
1,5-anhydroglucitol (1,5-AG) Assay
Severity:
major
Interaction type:
assay_interference
Nature:
absolute
Temporal spacing:
null
Description:
SGLT2 inhibitors like empagliflozin interfere with the 1,5-AG assay, a test for short-term glycemic control, making its results unreliable.
Actionable advice:
Avoid using the 1,5-AG assay for monitoring blood sugar control while on this medication.
Target id:
/biomarker/hematocrit
Target name:
Hematocrit
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Due to its diuretic effect causing plasma volume contraction, empagliflozin can cause a small, expected increase in hematocrit (the proportion of red blood cells).
Actionable advice:
Be aware that a slight increase in hematocrit is a normal and expected finding on lab tests.
Target id:
/biomarker/ldl-c
Target name:
LDL Cholesterol
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Empagliflozin can cause a small, dose-dependent increase in LDL cholesterol levels, which should be monitored as part of routine care.
Actionable advice:
Monitor lipid panels periodically; this small increase is generally outweighed by the drug's cardiovascular benefits.